Spatial distribution of EGFR and KRAS mutation frequencies correlates with histological growth patterns of lung adenocarcinomas

International Journal of Cancer

Volumn 141, Issue 9, 2017, Pages 1841-1848

  Dietz, Steffen ^a,b   Harms, Alexander ^b,c   Endris, Volker ^c   Eichhorn, Florian ^d   Kriegsmann, Mark ^c   Longuespée, Rémi ^c   Stenzinger, Albrecht ^a,c   Sültmann, Holger ^a,b   Warth, Arne ^b,c   Kazdal, Daniel ^b,c  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b German Center for Lung Research (DZL)   (Germany)

^c UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

driver gene mutation allele frequency; heterogeneity; histological growth pattern; lung adenocarcinoma

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; K RAS PROTEIN; EGFR PROTEIN, HUMAN; KRAS PROTEIN, HUMAN; PROTEIN P21;

ADULT; AGED; ARTICLE; CANCER GROWTH; CELL COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENE MUTATION; GENETIC HETEROGENEITY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; MALE; ONCOGENE; ONCOGENE EGFR; ONCOGENE K RAS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; VERY ELDERLY; ADENOCARCINOMA; GENETICS; LUNG TUMOR; MIDDLE AGED; MUTATION; PATHOLOGY;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; FEMALE; GENE FREQUENCY; GENETIC HETEROGENEITY; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PROTO-ONCOGENE PROTEINS P21(RAS); RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 85028667032     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.30881     Document Type: Article

References (26)

1. Howlader N, Noone A, Krapcho M, et al. SEER cancer statistics review, 1975–2014, vol. 2017. National Cancer Institute: Bethesda, MD, 2017.
2. Swanton C, Govindan R. Clinical implications of genomic discoveries in lung cancer. N Engl J Med 2016;374:1864–73.
3. Roberts PJ, Stinchcombe TE. KRAS mutation: should we test for it, and does it matter? J Clin Oncol 2013;31:1112–21.
4. Kim ES. Chemotherapy resistance in lung cancer. Adv Exp Med Biol 2016;893:189–209.
5. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012;13:239–46.
6. Lederlin M, Puderbach M, Muley T, et al. Correlation of radio- and histomorphological pattern of pulmonary adenocarcinoma. Eur Respir J 2013;41:943–51.
7. Warth A, Muley T, Harms A, et al. Clinical relevance of different papillary growth patterns of pulmonary adenocarcinoma. Am J Surg Pathol 2016;40:818–26.
8. Warth A, Muley T, Kossakowski C, et al. Prognostic impact and clinicopathological correlations of the cribriform pattern in pulmonary adenocarcinoma. J Thorac Oncol 2015;10:638–44.
9. Warth A, Muley T, Meister M, et al. The novel histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification system of lung adenocarcinoma is a stage-independent predictor of survival. J Clin Oncol 2012;30:1438–46.
10. Weichert W, Warth A. Early lung cancer with lepidic pattern: adenocarcinoma in situ, minimally invasive adenocarcinoma, and lepidic predominant adenocarcinoma. Curr Opin Pulm Med 2014;20:309–16.
11. Tsao MS, Marguet S, Le Teuff G, et al. Subtype classification of lung adenocarcinoma predicts benefit from adjuvant chemotherapy in patients undergoing complete resection. J Clin Oncol 2015;33:3439–46.
12. Bai H, Wang Z, Wang Y, et al. Detection and clinical significance of intratumoral EGFR mutational heterogeneity in Chinese patients with advanced non-small cell lung cancer. PLoS One 2013;8:e54170.
13. Hata AN, Niederst MJ, Archibald HL, et al. Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition. Nat Med 2016;22:262–9.
14. Dietz S, Schirmer U, Merce C, et al. Low input whole-exome sequencing to determine the representation of the tumor exome in circulating DNA of non-small cell lung cancer patients. PLoS One 2016;11:e0161012.
15. Riediger AL, Dietz S, Schirmer U, et al. Mutation analysis of circulating plasma DNA to determine response to EGFR tyrosine kinase inhibitor therapy of lung adenocarcinoma patients. Sci Rep 2016;6:33505.
16. Mansuet-Lupo A, Zouiti F, Alifano M, et al. Intratumoral distribution of EGFR mutations and copy number in metastatic lung cancer, what impact on the initial molecular diagnosis? J Transl Med 2014;12:131.
17. Zhang J, Fujimoto J, Zhang J, et al. Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. Science 2014;346:256–9.
18. Jamal-Hanjani M, Wilson GA, McGranahan N, et al. Tracking the evolution of non-small-cell lung cancer. N Engl J Med 2017;376:2109–21.
19. Travis WD, Brambilla E, Nicholson AG, et al. The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol 2015;10:1243–60.
20. Kazdal D, Harms A, Endris V, et al. Prevalence of somatic mitochondrial mutations and spatial distribution of mitochondria in non-small cell lung cancer. Br J Cancer, 2017;117:220–226.
21. Endris V, Penzel R, Warth A, et al. Molecular diagnostic profiling of lung cancer specimens with a semiconductor-based massive parallel sequencing approach: feasibility, costs, and performance compared with conventional sequencing. J Mol Diagn 2013;15:765–75.
22. Pfarr N, Stenzinger A, Penzel R, et al. High-throughput diagnostic profiling of clinically actionable gene fusions in lung cancer. Genes Chromosomes Cancer 2016;55:30–44.
23. Campbell JD, Alexandrov A, Kim J, et al. Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas. Nat Genet 2016;48:607–16.
24. Cancer Genome Atlas Research N. Comprehensive molecular profiling of lung adenocarcinoma. Nature 2014;511:543–50.
25. Chaft JE, Arcila ME, Paik PK, et al. Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling. Mol Cancer Ther 2012;11:485–91.
26. Wang L, Hu H, Pan Y, et al. PIK3CA mutations frequently coexist with EGFR/KRAS mutations in non-small cell lung cancer and suggest poor prognosis in EGFR/KRAS wildtype subgroup. PLoS One 2014;9:e88291.